Patent ID: 8435970

Claim:
A combination comprising an ancillary compound and the compound 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, or a salt, tautomer or N-oxide thereof, wherein the ancillary compound is selected from: 1. hormones, hormone agonists, hormone antagonists and hormone modulating agents, wherein said hormones, hormone agonists, hormone antagonists and hormone modulating agents are selected from corticosteroids, antiandrogens, antiestrogens and GNRAs; 2. cytokines and cytokine activating agents; 3. retinoids and rexinoids 4. monoclonal antibodies to cell surface antigen(s); 5. camptothecin compounds, wherein the camptothecin compound is selected from camptothecin and topotecan; 6. antimetabolites wherein the antimetabolite is selected from gemcitabine, capecitabine, cytarabine, ralitrexed, pemetrexed and methotrexate; or 6-mercapto purine, 6-thioguanine, cladribine, 2′-deoxycoformycin and hydroxyurea; 7. vinca alkaloids, wherein the vinca alkaloid is selected from vindesine, vinvesir, vinblastine, vincristine and vinorelbine; 8. taxanes, wherein the taxane is selected from paclitaxel and docetaxel; 9. epothilones; 10. platinum compounds, wherein the platinum compound is selected from chloro(diethylenediamino)-platinum (II) chloride; dichloro(ethylenediamino)-platinum (II); spiroplatin; iproplatin; diamino(2-ethylmalonato)platinum (II); (1,2-diaminocyclohexane)malonatoplatinum (II); (4-carboxyphthalo)-(1,2-diaminocyclohexane)platinum (II); (1,2-diaminocyclohexane)-(isocitrato)platinum (II); (1,2-diaminocyclohexane)-cis-(pyruvato)platinum (II); onnaplatin; tetraplatin, carboplatin or oxaliplatin; 11. Topo II inhibitors, wherein said Topo II inhibitors are selected from daunorubicin, idarubicin, epirubicin; or is selected from etoposide a and teniposide; or is mitoxantrone; or is selected from losoxantrone and actinomycin D; 12. alkylating agents wherein said alkylating agents are selected from aziridine, busulfan, nitrogen mustard and nitrosourea alkylating agents; 13. signalling inhibitors, wherein said signalling inhibitor is selected from sunitinib, trastuzumab, cetuximab, gefitinib, erlotinib, bevacizumab, imatinib mesylate, sorafenib, dasatinib, lapatinib, nilotinib, vandetanib, vatalinib, CHIR-258, and axitinib; 14. CDK inhibitors, wherein said CDK inhibitors are ancillary CDK inhibitors; 15. COX-2 inhibitors; 16. HDAC inhibitors; 17. Selective immunoresponse modulators; 18. DNA methyl transferase inhibitors; 19. proteasome inhibitors; 20. Aurora inhibitors, wherein said Aurora inhibitors are ancillary Aurora inhibitors; 21. Hsp90 inhibitors; 22. Checkpoint targeting agents selected from polo-like kinase inhibitors (Plks), CHK kinase inhibitors, inhibitors of the BUB kinase family and kinesin inhibitors; 23. DNA repair inhibitors; and 24. Inhibitors of G-protein coupled receptor.